GARNL3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06552(GARNL3 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P06552(GARNL3 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The GARNL3 (GTPase Activating RANGAP Domain Like 3) antibody is a research tool used to study the GARNL3 protein, a member of the GTPase-activating protein (GAP) family. GARNL3 is implicated in regulating small GTPases, particularly those in the Ras superfamily, which are critical for intracellular signaling, cell cycle progression, and cytoskeletal organization. The protein contains a conserved RANGAP domain, which is associated with GTP hydrolysis activity, suggesting a role in modulating GTPase-dependent pathways. Dysregulation of GARNL3 has been linked to neurological disorders and cancer, though its precise mechanistic contributions remain under investigation.

The GARNL3 antibody enables detection and quantification of the protein in various experimental contexts, such as Western blotting, immunohistochemistry, and immunofluorescence. Researchers utilize it to explore GARNL3’s expression patterns across tissues, its subcellular localization, and interactions with binding partners. Studies have highlighted its potential involvement in synaptic function and neuronal development, with altered expression observed in conditions like autism spectrum disorders and glioblastoma. Additionally, GARNL3’s interaction with mTOR signaling components suggests a possible role in cellular growth and metabolic regulation. As a relatively novel target, ongoing research aims to clarify its physiological and pathological roles, with the antibody serving as a key reagent for validating findings in disease models and elucidating molecular pathways. Its development underscores the growing interest in GTPase regulatory networks as therapeutic targets.